This study also showed that HER2-driven tumours ultimately cannot escape the total inactivation of HER2 (Sergina et al, 2007), leaving hope that more potent TKIs or higher doses of TKIs may yet show significant activity in this disease. This evidence concerns the gene ERBB2 and neoplasm.